Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Medivation (MDVN) upgraded to Buy at Canaccord by analyst John Newman who cited increased confidence in the Xtandi breast cancer program as well as "encouraging data" for talazoparib in ovarian cancer. Newman added that the latter is wholly owned by Medivation, meaning 100% of profits will flow through to the company. 2. BlackRock (BLK) upgraded to Buy at Citi with analyst William Katz saying that he views the company as an "increasingly differentiated winner" following the Department of Labor fiduciary rule. The analyst sees a "significant runway" of growth for BlackRock's iShares and highlights its opportunity to commercialize FutureAdvisor. 3. Devon Energy (DVN) upgraded to Overweight at Morgan Stanley by analyst Evan Callo, who said the recent stabilization in oil price increases the likelihood Devon will be successful with asset sales and places focus on E&P future upside to medium-term commodity price recovery and operating leverage. 4. Lennox (LII) upgraded to Buy at Seaport Global with analyst Walt Liptak saying Q1 commercial HVAC and residential HVAC trends were better-than-expected and suggest 2016 is tracking better than expected. 5. Panera Bread (PNRA) upgraded to Buy at Jefferies by analyst Alexander Slagle saying the market is underestimating the company's earnings power over the next few years. KeyBanc analyst Chris O'Cull added that the company's investments over the past few years will drive earnings growth for the first time in two years and push results above Street expectations. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

Wells Fargo analyst Joseph O'Dea lowered the firm's price target on Lennox to $520 from $545 and keeps an Overweight rating on the shares. A solid Q1 and full year raise still saw Lennox's stock down 2% vs. XLI down 80bps, the firm says. Wells thinks a lighter potential R454B tailwind in 2025 and M&A uncertainty overhang are two reasons. In the firm's view, growth potential remains compelling.

Consensus $19.72. Backs FY24 revenue up 7%, consensus $5.12B. Sees FY24 free cash flow $500M-$600M.